MANAGEMENT OF ADVANCED PROSTATE CANCER

1. Natural History of High-Risk Prostate Cancer
2. Identifying the Best Candidate for Radical Prostatectomy in High-Risk Prostate Cancer
3. Neoadjuvant Therapy Prior to Radical Prostatectomy
4. Robot-Assisted Radical Prostatectomy for High-Risk Prostate Cancer
5. Pelvic Lymphadenectomy for High-Risk Prostate Cancer
6. Adjuvant Therapy in Locally Advanced Prostate Cancer
7. Role of Radical Prostatectomy in the Management of Metastatic Prostate Cancer
8. The Roles of Radiotherapy, Androgen Deprivation Therapy, and Their Combination for Locally Advanced Prostate Cancer
9. External Beam Radiotherapy for Advanced Prostate Cancer: Dose, Technique, and Fractionation
10. Radiotherapy for Prostate Cancer Patients with Pelvic Lymph Node Metastasis
11. Emerging Role of Radiotherapy in Stage IV Prostate Cancer
12. Adjuvant and Salvage Radiation Therapy for Prostate Cancer After Radical Prostatectomy
13. Immediate vs. Delayed ADT for Recurrent Prostate Cancer
14. Intermittent Versus Continuous ADT for Advanced Prostate Cancer
15. LHRH Agonist and Antagonist for Prostate Cancer
16. Abiraterone or Enzalutamide in Chemotherapy-Naïve Metastatic CRPC
17. Abiraterone or Enzalutamide in CRPC After Chemotherapy
18. Clinical Results of Secondary Hormonal Treatment
19. Side Effects and Management of ADT for Prostate Cancer
20. Systemic Chemotherapy for Metastatic Hormone-Sensitive Prostate Cancer
21. Systemic Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
22. Radiopharmaceutical Therapy in Metastatic CRPC
23. Immunotherapy for CRPC
24. Clinical Trials in CRPC
25. Palliative Care for Metastatic Symptomatic CRPC

This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.

Features
• Summarizes the state of the art in the management of locally advanced and metastatic prostate cancer
• Evaluates the role of abiraterone and enzalutamide, docetaxel-based chemotherapy, and novel agents
• Discusses surgical approaches and the role of adjuvant and neoadjuvant therapy
• Examines current radiotherapy techniques

Author
Choung Soo Kim, M.D., Professor, Department of Urology, Asan Medical Center, Asan Medical Center Ulsan University, Seoul, Republic of Korea.